Is Guardant Health (GHR) stock a good buy?
Guardant Health has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $138.40, Guardant Health has a forecasted upside of 139.0% from its current price of $57.92.
Where can I buy GH shares?
Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What was the price of the IPO of (GH) in 2018?
(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share.
What was the price of the Guardant Health IPO?
(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. What is Guardant Health's stock symbol?
Is GH a good stock to buy?
The consensus among 4 Wall Street analysts covering (NASDAQ: GH) stock is to Strong Buy GH stock.
Why is Guardant Health stock dropping?
The problem for the company is that merely meeting expectations was not enough considering the premium valuation the stock was trading at prior to the report. Guardant Health's shares are now down more than 70% from the 52-week high. However, it still trades at nearly 17 times sales.
Is Guardant health a buy?
Guardant Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Who owns Guardant health?
--(BUSINESS WIRE)-- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.
Is GH a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is Guardant health a good company?
Is Guardant Health a good company to work for? Guardant Health has an overall rating of 3.7 out of 5, based on over 159 reviews left anonymously by employees. 67% of employees would recommend working at Guardant Health to a friend and 65% have a positive outlook for the business.
Is Guardant Health publicly traded?
REDWOOD CITY, Calif. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $19.00 per share.
Is Guardant a biotech company?
Guardant Health, Inc. operates as a biotechnology company.
What type of company is Guardant?
precision oncology companyGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.
Is Guardant360 FDA approved?
On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360CDx for comprehensive genomic profiling across all solid cancers and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) alterations who may benefit from ...
Should I buy or sell Guardant Health stock right now?
11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 1...
What is Guardant Health's stock price forecast for 2022?
11 Wall Street research analysts have issued 1 year target prices for Guardant Health's shares. Their GH stock forecasts range from $65.00 to $165....
How has Guardant Health's stock performed in 2022?
Guardant Health's stock was trading at $100.02 at the start of the year. Since then, GH shares have decreased by 62.5% and is now trading at $37.50...
When is Guardant Health's next earnings date?
Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Guar...
How were Guardant Health's earnings last quarter?
Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, May, 5th. The company reported ($1.21) earnings per share for...
What guidance has Guardant Health issued on next quarter's earnings?
Guardant Health updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share guidance of for the period. The...
Who are Guardant Health's key executives?
Guardant Health's management team includes the following people: Dr. Helmy Eltoukhy Ph.D. , Co-Founder, Co-CEO & Chairman (Age 43, Pay $275.66k)...
What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?
52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com . Helmy Eltoukhy has an approval rating of 95% among Guardant Health's...
Who are some of Guardant Health's key competitors?
Some companies that are related to Guardant Health include Exact Sciences (EXAS) , Natera (NTRA) , Elekta AB (publ) (EKTAY) , Fulgent Genetics...
What is the GH symbol?
Guardant Health trades on the NASDAQ under the ticker symbol "GH."
How much does Guardant Health make?
How much money does Guardant Health make? Guardant Health has a market capitalization of $12.04 billion and generates $286.73 million in revenue each year . The company earns $-253,780,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.
What is the official website of Guardant Health?
The official website for Guardant Health is www.guardanthealth.com.
What is the P/E ratio of Guardant Health?
The P/E ratio of Guardant Health is -22.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is Guardant Health a buy or sell company?
Guardant Health has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Does Guardant Health pay dividends?
Guardant Health does not currently pay a dividend.
Content From Our Affiliates
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer.
Profile
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer.
